Thread: Sabcs 2012
View Single Post
Old 12-07-2012, 07:28 PM   #1
Lani
Senior Member
 
Join Date: Mar 2006
Posts: 4,778
Sabcs 2012

They are all singing the praises of Pertuzumab and TDM-1 and predicting the latter will be approved during the next 2-3 months.

Dr Slamon declared her2 + breast cancer has gone from being one of the worst to one of the best types to have.

Lots of options of chemos to add to herceptin including Navelbine and Halaven(erbulin), mtor inhibitors too.

30% of talks on her2+ breast cancer.

Too much info to digest yet. Amount of info is dizzying-- have to rest before posting.

Great results for perjeta and TDM1.

Fabulous lecture by Dr. Yosef Yarden who worked with Dr Ulrich developing herceptin and has theorized a two hit theory of the development of her2+ breast cancer --first hit is her2, second is p53 directly or indirectly.

Explans why so many her2+ tumors
have adjacent DCIS, why there is more her2+ DICS than IDC.

Spoke with someone who has started a tissue and blood bank that I think it would be good to donate to for those whose tumors are at community hospitals (and will be disposed of anyway after 5 years ) .

Things are hopping-- more options becoming available.
Lani is offline   Reply With Quote